AstraZeneca exec tells Congress it could have 50 million doses of its COVID-19 vaccine ready in April
Shares of AstraZeneca were up 0.1% in after-hours trading on Tuesday after a company executive testified before Congress that the drug maker expects to deliver 50 million of its experimental COVID-19 vaccine in the U.S. in April if it's authorized before then. That would be enough to vaccinate 25 million people. AstraZeneca's COVID-19 vaccine has been authorized for use in some other countries, including the U.K.; however, it is currently in phase 3 clinical studies in the U.S. "Based on current projections, assuming [emergency use authorization], we expect to deliver up to 50 million doses by the end of April," Ruud Dobber, president of North America business for AstraZeneca, told members of the House Subcommittee on Oversight and Investigations on Tuesday, according to a spokesperson. The trial finished enrollment in January but the company has not yet released any clinical data for the U.S. arm of the study. AstraZeneca's stock is down 0.2% over the past 12 months, while the broader S&P 500 is up 16.1%.
Portions of AstraZeneca were up 0.1% in night-time exchanging on Tuesday after an organization leader affirmed before Congress that the medication creator hopes to convey 50 million of its trial COVID-19 antibody in the U.S. in April on the off chance that it's approved previously. That would be sufficient to immunize 25 million individuals. AstraZeneca's COVID-19 immunization has been approved for use in some different nations, including the U.K.; notwithstanding, it is presently in stage 3 clinical investigations in the U.S. "In light of current projections, accepting [emergency use authorization], we hope to convey up to 50 million dosages before the finish of April," Ruud Dobber, leader of North America business for AstraZeneca, told individuals from the House Subcommittee on Oversight and Investigations on Tuesday, as per a representative. The preliminary completed enlistment in January yet the organization has not yet delivered any clinical information for the U.S. arm of the examination. AstraZeneca's stock is down 0.2% in the course of recent months, while the more extensive S&P 500 is up 16.1%. Market Pulse Stories are Rapid-fire, short news blasts on stocks and markets as they move.